| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 05/16/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 63.6k | $1.07 | $67.9k | | 05/16/2023 |
| 03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 6.4k | $0.88 | $5.6k | | 03/01/2023 |
| 03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 1.1k | $0.88 | $974 | | 03/01/2023 |
| 03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 6.6k | $0.88 | $5.8k | | 03/01/2023 |
| 02/27/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 7.5k | $0.81 | $6.1k | | 02/27/2023 |
| 08/31/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 1.1k | $0.36 | $415.8 | | 08/31/2022 |
| 03/01/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 1.1k | $2.17 | $2.4k | | 02/28/2022 |
| 03/01/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 6.6k | $2.17 | $14.2k | | 02/28/2022 |
| 02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 60k | $0.00 | $0 | | 02/28/2022 |
| 02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 7.4k | $2.15 | $15.9k | | 02/28/2022 |
| 02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 225k | $2.16 | $486k | | 02/28/2022 |
| 08/31/2021 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 1k | $2.83 | $2.9k | | 08/31/2021 |
| 03/16/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 10.4k | $0.00 | $0 | | 03/16/2021 |
| 03/01/2021 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 7.6k | $3.40 | $25.7k | | 02/26/2021 |
| 02/26/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 120k | $3.46 | $415.2k | | 02/26/2021 |
| 02/26/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 70k | $0.00 | $0 | | 02/26/2021 |
| 02/28/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 62k | $0.00 | $0 | | 02/28/2020 |
| 02/28/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Stock Option (Right to buy) | 105.5k | $8.87 | $935.8k | | 02/28/2020 |
| 11/20/2019 | Akebia Therapeutics, Inc. | AKBA | Purchase | Common Stock | 27k | $3.58 | $96.7k | | 11/20/2019 |
| 08/30/2019 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 10k | $0.00 | $0 | | 08/30/2019 |
| 08/30/2019 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 250k | $4.13 | $1M | | 08/30/2019 |
| 03/15/2019 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 7.3k | $0.00 | $0 | See footnote | 03/15/2019 |
| 03/15/2019 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 7.3k | $0.00 | $0 | | 03/15/2019 |
| 03/15/2019 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 7.3k | $0.00 | $0 | | 03/15/2019 |
| 03/15/2019 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 7.3k | $0.00 | $0 | See footnote | 03/15/2019 |
| 01/18/2019 | Protara Therapeutics, Inc. | PRTO | Grant | Stock Option (Right to Buy) | 145k | $2.64 | $382.8k | | 01/18/2019 |
| 12/31/2018 | Protara Therapeutics, Inc. | PRTO | Grant | Common Stock | 2.4k | $1.93 | $4.7k | | 12/31/2018 |
| 06/29/2018 | Protara Therapeutics, Inc. | PRTO | Grant | Common Stock | 10k | $1.62 | $16.2k | | 06/29/2018 |
| 01/17/2018 | Protara Therapeutics, Inc. | PRTO | Grant | Stock Option (Right to Buy) | 200k | $2.85 | $570k | | 01/17/2018 |
| 12/29/2017 | Protara Therapeutics, Inc. | PRTO | Grant | Common Stock | 3.9k | $1.30 | $5.1k | | 12/29/2017 |
| 12/15/2017 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 3.3k | $0.00 | $0 | See footnote | 12/15/2017 |
| 12/15/2017 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 3.3k | $0.00 | $0 | | 12/15/2017 |
| 12/15/2017 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 3.3k | $0.00 | $0 | | 12/15/2017 |
| 12/15/2017 | Protara Therapeutics, Inc. | PRTO | Purchase | Common Stock | 12k | $1.88 | $22.6k | | 12/15/2017 |
| 12/15/2017 | Protara Therapeutics, Inc. | PRTO | Gift | Common Stock | 3.3k | $0.00 | $0 | See footnote | 12/15/2017 |
|